ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,187.70
0.00%
US Tech 100
17,517.22
-0.54%
다우존스 지수
38,884.26
0.00%
Bitcoin
62,177.51
-0.25%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Hyloris Pharmaceuticals SA (HYL)

  7. Hyloris Pharmaceuticals SA (HYL) 뉴스

HYL

Hyloris Pharmaceuticals (HYL)

Hyloris Pharmaceuticals SA
일자:
정렬 기준:
 검색 관련기사 보기:EU:HYL
일자시간출처헤드라인심볼기업
2024/03/1415:00GlobeNewswire Inc.Hyloris Présente ses Résultats Annuels pour 2023 et ses PerspectivesEU:HYLHyloris Pharmaceuticals SA
2024/03/1415:00GlobeNewswire Inc.Hyloris Reports Full Year Results for 2023 & Provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
2024/03/1414:59GlobeNewswire Inc.Communication at the request of the FSMA on the transactions with QliniqEU:HYLHyloris Pharmaceuticals SA
2024/03/1414:59GlobeNewswire Inc.Communiqué à la requête de la FSMA sur les transactions avec QliniQEU:HYLHyloris Pharmaceuticals SA
2024/03/0815:00GlobeNewswire Inc.Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024EU:HYLHyloris Pharmaceuticals SA
2024/03/0815:00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
2024/03/0815:00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
2024/02/2802:00GlobeNewswire Inc.Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au CanadaEU:HYLHyloris Pharmaceuticals SA
2024/02/2802:00GlobeNewswire Inc.Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaEU:HYLHyloris Pharmaceuticals SA
2024/02/1502:00GlobeNewswire Inc.Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental ProceduresEU:HYLHyloris Pharmaceuticals SA
2024/02/1502:00GlobeNewswire Inc.Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions DentairesEU:HYLHyloris Pharmaceuticals SA
2024/01/3015:00GlobeNewswire Inc.Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)EU:HYLHyloris Pharmaceuticals SA
2024/01/3015:00GlobeNewswire Inc.Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)EU:HYLHyloris Pharmaceuticals SA
2024/01/1903:00GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)EU:HYLHyloris Pharmaceuticals SA
2024/01/1903:00GlobeNewswire Inc.Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703:30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703:30GlobeNewswire Inc.La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)EU:HYLHyloris Pharmaceuticals SA
2024/01/1703:30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
2024/01/1701:30GlobeNewswire Inc.Pleco Therapeutics receives FDA Orphan Drug DesignationEU:HYLHyloris Pharmaceuticals SA
2023/12/2702:00GlobeNewswire Inc.Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension oraleEU:HYLHyloris Pharmaceuticals SA
2023/12/2202:30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
2023/12/2202:30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
2023/12/2202:30GlobeNewswire Inc.Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche BrûlanteEU:HYLHyloris Pharmaceuticals SA
2023/12/0415:00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
2023/12/0415:00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
2023/12/0415:00GlobeNewswire Inc.Hyloris annonce l'approbation du Gel Podofilox par la FDA américaineEU:HYLHyloris Pharmaceuticals SA
2023/10/2414:00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
2023/10/2414:00GlobeNewswire Inc.Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au CanadaEU:HYLHyloris Pharmaceuticals SA
2023/10/2414:00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
2023/09/0705:00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
 검색 관련기사 보기:EU:HYL

최근 히스토리

CCOM
US30
US 30
NYSE
JPM
JP Morgan Chase
AMEX
SPY
SPDR S&P 500
NYSE
XOM
Exxon Mobil
NYSE
CVX
Chevron
AMEX
XLV
Health Care Select Sector
COIN
ETHUSD
Ethereum
FX
USDGBP
US Dollar vs Sterling
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유